[Table_ReportDate] 2025 年 11 月 24 日 [Table_ReportType] 医药生物行业周报（11 月第 3 周） [Table_S 行业ummary 观点：] [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G IVD 巨头共识下注肿瘤早筛 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（11 月 17 日-11 月 21 日）医药生物 板块收跌 6.88%，跑输 Wind 全 A（-5.13%）和沪深 300 （-3.77%）。从细分板块来看，所有子板块均收跌，原 料药（-8.6%）、线下药店（-8.58%）和其他生物制品 领跌（-7.99%）领跌。从个股来看，海南海药（23.8%）、 *ST 长药（19.7%）和*ST 苏吴（15.5 ...

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

11月24日，浩欧博涨5.1%，截至发稿，报183.80元/股，成交1.46亿元，换手率1.30%，总市值116.68亿 元。 资料显示，江苏浩欧博生物医药股份有限公司位于苏州工业园区东堰里路9号，成立日期2009年6月8 日，上市日期2021年1月13日，公司主营业务涉及从事体外诊断试剂的研发、生产和销售。主营业务收 入构成为：试剂销售89.46%，其他销售5.86%，仪器销售3.84%，租赁销售0.85%。 从基金十大重仓股角度 数据显示，兴业基金旗下1只基金重仓浩欧博。兴业医疗保健A（011466）三季度持有股数9.69万股，占 基金净值比例为3.8%，位居第十大重仓股。根据测算，今日浮盈赚取约86.43万元。 兴业医疗保健A（011466）成立日期2021年3月8日，最新规模2.61亿。今年以来收益19.11%，同类排名 3578/8209；近一年收益11.73%，同类排名4678/8129；成立以来亏损22.64%。 兴业医疗保健A（011466）基金经理为陈旭。 截至发稿，陈旭累计任职时间4年263天，现任基金资产总规模4.04亿元，任职期间最佳基金回 报-22.64%， 任职期间最差基金回报-2 ...

2025年11月20日，全球医疗科技巨头 雅培 Abbott Laboratories 正式宣布，将以现金方式收购美国精准诊断公 司 Exact Sciences ，总对价约 210亿美元 （约合人民币1493亿）。该交易预计于2026年上半年完成，成为 Abbott近年来规模最大、影响最深远的一笔并购案。 消息发布后，Exact Sciences股价在美股盘前大涨超过30%，市值突破200亿美元。业内普遍认为，此次收购将 显著改变全球癌症筛查与分子诊断的竞争格局，也标志着Abbott在高增长诊断赛道的战略转型正式落地。 # 公 司背景 与 双 方 定 位 Abbott成立于1888年，是全球领先的综合医疗科技企业，业务涵盖营养品、医疗器械、心血管介入、糖尿病管 理与体外诊断等多个领域。过去十年，Abbott凭借i-STAT与ARCHITECT系列分析仪在体外诊断市场稳居前 列，但随着疫情红利消退，其核心诊断业务增长趋缓，公司亟需寻找新的高壁垒、高成长赛道以维持营收动 力。 Exact Sciences成立于1995年，总部位于美国威斯康星州麦迪逊，是全球非侵入性癌症筛查与精准诊断的领先 企业。公司依托分子检 ...

11月21日，睿昂基因跌5.44%，成交额3290.94万元。两融数据显示，当日睿昂基因获融资买入额435.68 万元，融资偿还217.52万元，融资净买入218.16万元。截至11月21日，睿昂基因融资融券余额合计 5936.47万元。 分红方面，睿昂基因A股上市后累计派现1943.57万元。 融资方面，睿昂基因当日融资买入435.68万元。当前融资余额5936.47万元，占流通市值的4.02%，融资 余额低于近一年30%分位水平，处于低位。 责任编辑：小浪快报 融券方面，睿昂基因11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，上海睿昂基因科技股份有限公司位于上海市奉贤区汇丰西路1817弄147号，成立日期2012年2 月17日，上市日期2021年5月17日，公司主营业务涉及体外诊断产品(包括检测仪器及检测试剂)的研 发、生产、销售及科研、检测服务,主要为血液病(白血病、淋巴瘤)、实体瘤(肺癌、结直肠癌、黑色素 瘤等)和传染病(乙型肝炎、风疹、单纯疱疹等)患者提供基因及抗原的精 ...

截至发稿，之江生物市值为41亿元。 每经AI快讯，之江生物（SH 688317，收盘价：21.2元）11月23日晚间发布公告称，截至2025年11月21 日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份约101万股，占公司当前 总股本约1.92亿股的比例为0.53%，回购成交的最高价为22.86元/股，最低价为21.52元/股，支付的资金 总额为人民币约2237万元。 2024年1至12月份，之江生物的营业收入构成为：体外诊断行业占比98.25%，其他业务占比1.75%。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——"抛售日本"？GDP负增长，股市跳水，国债被抛，日元贬值！高市早苗"亡 命一搏"："灌水"21万亿！专家：恐赴"特拉斯风暴"后尘 ...

Group 1 - The core point of the news is that 热景生物 has repurchased approximately 900,000 shares, which is about 0.98% of its total share capital, with a total expenditure of approximately 150 million RMB [1] - The share repurchase was conducted through centralized bidding, with the highest transaction price being 176.79 RMB per share and the lowest at 145.59 RMB per share [1] - As of the announcement date, the market capitalization of 热景生物 is 15.2 billion RMB [2] Group 2 - For the fiscal year 2024, the revenue composition of 热景生物 is primarily from in vitro diagnostic products, accounting for 98.85%, while other businesses contribute 1.15% [1]

中经记者 苏浩 卢志坤 北京报道 （利德曼大楼外景 公司官网/图） 一家业绩承压的体外诊断企业，一笔溢价162%的收购交易，正共同勾勒出利德曼（300289.SZ）跨界转 型之旅。 标的成色待考 此次收购标的先声祥瑞成立于2000年，主要从事生物制品（体内诊断试剂、疫苗）及体外诊断试剂的研 发、生产和销售，目前核心产品聚焦于结核筛查与诊断领域。 根据审计报告，截至2025年7月31日，先声祥瑞合并口径股东权益账面值为10.2亿元。经收益法评估， 先声祥瑞全部权益评估值高达26.74亿元，较账面价值增值16.54亿元，增值率162.23%。利润分配调整 后，先声祥瑞100%股权价值调整为24.81亿元，其70%股权对应价值为17.38亿元，最终交易作价17.33亿 元。 如此高的估值溢价，主要基于对标的公司未来盈利能力的预期。根据备考审阅报告，本次交易完成后， 利德曼合并资产负债表中将形成约10.19亿元的商誉。利德曼在草案中也提示，若标的公司实际盈利水 平显著低于预期，本次交易形成的商誉可能进行减值，从而影响公司经营业绩。 反观先声祥瑞近年来的财务表现，呈现出较大波动性。有关数据显示，该公司2023年、202 ...

Core Viewpoint - The stock price of Shengxiang Bio has experienced a decline of 9.42% year-to-date, with significant recent drops in the last five, twenty, and sixty trading days [1] Company Overview - Shengxiang Bio, established on April 23, 2008, and listed on August 28, 2020, is located in Changsha High-tech Industrial Development Zone, Hunan Province. The company focuses on innovative gene technology, encompassing the R&D, production, and sales of diagnostic reagents and instruments, as well as third-party medical testing services [1] - The revenue composition of Shengxiang Bio includes 87.39% from diagnostic reagents, 5.71% from diagnostic instruments, 4.55% from testing services, and 2.34% from other sources [1] Financial Performance - For the period from January to September 2025, Shengxiang Bio achieved a revenue of 1.244 billion yuan, representing a year-on-year growth of 20.49%. However, the net profit attributable to the parent company was 191 million yuan, reflecting a decrease of 2.10% year-on-year [2] - Since its A-share listing, Shengxiang Bio has distributed a total of 2.363 billion yuan in dividends, with 1.467 billion yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders of Shengxiang Bio increased by 4.17% to 21,600, with an average of 26,772 circulating shares per person, a decrease of 4.01% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF holds 9.8053 million shares, down by 1.7872 million shares from the previous period, while Hong Kong Central Clearing Limited is a new shareholder with 3.6601 million shares [3]

东方海洋所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：低价、水产品、预制 菜、微盘股、民营医院等。 11月21日，东方海洋盘中上涨2.11%，截至09:35，报2.91元/股，成交2.23亿元，换手率5.12%，总市值 57.01亿元。 资金流向方面，主力资金净流出2756.78万元，特大单买入3036.92万元，占比13.63%，卖出5686.95万 元，占比25.52%；大单买入5764.66万元，占比25.86%，卖出5871.41万元，占比26.34%。 东方海洋今年以来股价涨0.69%，近5个交易日涨6.99%，近20日涨8.99%，近60日涨0.34%。 今年以来东方海洋已经4次登上龙虎榜，最近一次登上龙虎榜为3月20日，当日龙虎榜净买入1219.64万 元；买入总计1.56亿元 ，占总成交额比12.08%；卖出总计1.44亿元 ，占总成交额比11.14%。 资料显示，山东东方海洋科技股份有限公司位于山东省烟台市莱山区澳柯玛大街18号，成立日期2001年 12月19日，上市日期2006年11月28日，公司主营业务涉及从事海水苗种繁育、养殖,水产品加工,生物科 技,保税仓储物流以及 ...